Raltegravir

CAS : 518048-05-0

Ref. 3D-FR29048

Informations sur le produit

• Nom: Raltegravir
• Synonymes: N-((4-Fluorophenyl)methyl)-1,6-dihydro-5-hydroxy-1-methyl-2-(1-methyl-1-(((5-methyl-1,3,4-oxadiazol-2-yl)carbonyl)amino)ethyl)-6-oxo -4-pyrimidinecarboxamide, 4-Pyrimidinecarboxamide, N-[(4-fluorophenyl)methyl]-1,6-dihydro-5-hydroxy-1-methyl-2-[1-methyl-1-[[(5-methyl-1,3,4-oxadiazol-2-yl)carbonyl]amino]ethyl]-6-oxo-, 5-Hydroxy-2-[1-[[(5-Methyl-1,3,4-oxadiazol-2-yl)carbonyl]amino]-1-methylethyl]-N-(4-fluorobenzyl)-1-methyl-6-oxo-1,6-dihydropyrimidine-4-carboxamide, N-(4-fluorobenzyl)-5-hydroxy-1-methyl-2-(1-methyl-1-{[(5-methyl-1,3,4-oxadiazol-2-yl)carbonyl]amino}ethyl)-6-oxo-1,6-dihydropyrimidine-4-carboxamide, N-[(4-Fluorophenyl)methyl]-1,6-dihydro-5-hydroxy-1-methyl-2-[1-methyl-1-[[(5-methyl-1,3,4-oxadiazol-2-yl)carbonyl]amino]ethyl]-6-oxo-4-pyrimidinecarboxamide

Description

Raltegravir is an antiviral drug that is used in the treatment of HIV-1 infection. It has been shown to be highly effective in preventing viral resistance to other antiretroviral drugs, such as protease inhibitors, by inhibiting the replication of HIV-1. Raltegravir binds noncompetitively to the reverse transcriptase enzyme and prevents it from converting single-stranded RNA into double-stranded DNA. In addition, raltegravir inhibits the activity of proteases and polymerases that are necessary for viral replication. Raltegravir has been shown to inhibit the growth of resistant mutants at a concentration of 250 nanomolar. The chemical structure of this drug was determined using X-ray crystallography and nuclear magnetic resonance spectroscopy.

• Marque: Biosynth

Propriétés chimiques

• Masse moléculaire: 444.42 g/mol
• Formule: C₂₀H₂₁FN₆O₅
• Degré de pureté: Min. 98 Area-%
• Couleur/Forme: White Off-White Powder